Prolonged endotracheal intubation in intensive care units (ICUs) is a frequent and clinically challenging aspect of managing critically ill patients. While intubation is essential for airway protection and adequate ventilation, its extended use is associated with a substantial risk of complications, including laryngeal and tracheal injury, ventilator-associated pneumonia, increased sedation requirements, prolonged mechanical ventilation, longer ICU stays, and higher mortality. In this setting, tracheotomy represents an important therapeutic alternative for patients anticipated to require long-term respiratory support.

This paper aims to examine the challenges of prolonged intubation, outline its most common complications, and explore the issue of optimal timing for tracheotomy. Particular attention is given to the comparison between early and late tracheotomy and their impact on key clinical outcomes, such as duration of mechanical ventilation, infection rates, patient comfort, sedation needs, and overall length of hospitalization. Evidence from the literature indicates that timely consideration of tracheotomy, combined with an individualized approach based on the patient’s clinical status and prognosis of the underlying condition, may reduce complication rates, facilitate ventilator weaning, and improve overall outcomes.

Furthermore, decision-making regarding tracheotomy is influenced by several factors, including the primary diagnosis, neurological status, expected duration of ventilatory support, and the risk of extubation failure. Modern clinical practice emphasizes the use of structured weaning protocols and close multidisciplinary collaboration among intensivists, anesthesiologists, otorhinolaryngologists, and nursing staff. This coordinated approach supports early identification of appropriate candidates for tracheotomy, reduces variability in clinical practice, and enhances patient safety.

In conclusion, determining the timing of tracheotomy requires careful assessment of risks and benefits within a multidisciplinary framework. Although no universally optimal time point exists, early recognition of patients likely to need prolonged mechanical ventilation and timely intervention may provide significant clinical benefits in contemporary intensive care medicine.

Tranexamic acid (TXA) is an established antifibrinolytic therapy in the management of severely injured trauma patients with hemorrhage, demonstrating a proven effect on mortality reduction. Its mechanism of action is based on the inhibition of plasminogen activation, thereby stabilizing fibrin clot formation and limiting the progression of trauma-induced coagulopathy. Contemporary evidence consistently indicates that the clinical efficacy of TXA is highly time-dependent. The greatest reduction in mortality is achieved when administration is initiated early after injury, particularly within the first 3 hours, while delayed treatment is associated with a substantial loss of clinical benefit. Prehospital administration is additionally linked to improved outcomes, emphasizing the importance of minimizing time to treatment delivery within emergency care systems. Pharmacokinetic and clinical data indicate that TXA achieves effective plasma concentrations rapidly, with intravenous administration remaining the standard due to its predictable bioavailability and precise dosing capability. Meta-analyses and systematic reviews confirm a reduction in mortality without a consistent increase in overall adverse events, although heterogeneous data regarding thromboembolic complications warrant further evaluation.

Observed variability in dosing regimens and clinical implementation highlights the lack of standardized protocols and underscores the need for further stratification of patients and harmonization of treatment strategies. The administration of TXA can therefore be considered a highly effective but time-sensitive intervention, whose full therapeutic potential depends on timely and system-integrated administration within trauma care systems.

The synchronous occurrence of a gastrointestinal stromal tumor (GIST) and pancreatic ductal adenocarcinoma (PDAC) is exceptionally rare and poses significant diagnostic and therapeutic challenges. We report a 67-year-old female presenting with biliary obstruction, right upper quadrant pain, and dyspeptic symptoms. CT imaging revealed a pancreatic head mass, while a submucosal gastric lesion was identified only intraoperatively. Laparotomy enabled excision of a pedunculated gastric GIST, whereas the unresectable pancreatic tumor involved critical vascular structures, necessitating a palliative double bypass comprising cholecystectomy, hepaticojejunostomy, gastrojejunostomy, and enteroenterostomy. Histopathology confirmed a low-risk GIST and a moderately differentiated PDAC with distinct immunohistochemical profiles, supporting the presence of two independent primary tumors.

This case underscores the critical importance of meticulous intraoperative exploration, particularly in the presence of atypical or incidentally discovered lesions, and demonstrates the durable palliation afforded by surgical bypass in unresectable PDAC. Beyond the clinical context, potential molecular overlaps—activation of MAPK/ERK and PI3K/AKT/mTOR pathways, VEGF-mediated angiogenesis, and defects in DNA repair—provide a plausible biological basis for the synchronous occurrence of these otherwise unrelated neoplasms, informing potential strategies for personalized therapy

Background: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), represents an important component of systemic therapy for metastatic colorectal cancer (mCRC). By inhibiting angiogenesis and promoting vascular normalization, bevacizumab enhances the efficacy of cytotoxic drugs. However, despite proven benefits, some uncertainties remain regarding its safety profile, particularly the risk of gastrointestinal perforation and other vascular toxicities. Materials and Methods: This retrospective, single-center, observational study included patients with histologically confirmed mCRC treated with combination chemotherapy and bevacizumab (FOLFOX/FOLFIRI + bevacizumab) at the Oncology Department of Zemun Clinical Hospital Center between July 2022 and July 2025. Efficacy was assessed according to RECIST 1.1 criteria, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and duration of response (DoR). Adverse events were classified according to CTCAE v6.0. Results: A total of 74 patients were analyzed (56.8% male; mean age 67 ± 9 years). The median PFS was 6.5 months (IQR 3–9.8), and DoR 7.3 months (95% CI 5.2–9.5). ORR was 35.1%, and DCR 82.4%. The most common toxicities were hypertension (12.2%) and proteinuria (10.9%), while gastrointestinal perforation was observed in 4.1% of patients—slightly higher than in larger real-world series, which may be related to locally advanced disease, peritoneal carcinomatosis, or an intact primary tumor. Conclusion: Bevacizumab-based therapy demonstrated consistent efficacy and an acceptable safety profile in patients with mCRC. Although the incidence of perforation and fistula formation was somewhat higher, the therapy remained safe with careful patient selection and monitoring.